Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Core Insights - Editas Medicine is advancing its lead candidate, EDIT-401, which has shown over 90% mean LDL-C reduction in preclinical studies and is on track for IND/CTA submission by mid-2026 [1][2][7] - The company is preparing to initiate its first-in-human clinical trial for EDIT-401 in patients with heterozygous familial hypercholesterolemia (HeFH), with early proof-of-concept data expected by the end of 2026 [1][2][7] - Editas has a strong cash position, with cash runway extending into the third quarter of 2027, allowing it to fund ongoing operations and development [1][5][10] Recent Achievements and Upcoming Milestones - The company reported a net loss of $5.6 million for Q4 2025, a significant reduction from a net loss of $45.4 million in Q4 2024 [6][10] - For the full year 2025, the net loss attributable to common stockholders was $160.1 million, down from $237.1 million in 2024 [10] - Collaboration and other research and development revenues increased to $40.5 million in 2025, compared to $32.3 million in 2024, driven by milestone achievements [10] Financial Overview - As of December 31, 2025, cash and cash equivalents were $146.6 million, down from $269.9 million in 2024, but sufficient to support operations until Q3 2027 [5][18] - Research and development expenses decreased to $90.0 million in 2025 from $199.2 million in 2024, primarily due to the discontinuation of the reni-cel program [10] - General and administrative expenses also decreased to $49.9 million in 2025 from $72.0 million in 2024, reflecting workforce reductions and lower professional service costs [10]